Quality Reliability Technology (405100) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Specializes in semiconductor and electronic component reliability testing, failure analysis, and equipment development, with a focus on expanding into AI, aerospace, and defense sectors.
Operates globally with subsidiaries in Hong Kong, USA, and China, and maintains a strong R&D focus with 46 research staff and 31 registered patents.
Financial highlights
2026 H1 consolidated revenue: KRW 38.9B, up 18.8% YoY; operating income: KRW 4.2B, up 13.8% YoY.
Net income attributable to owners: KRW 3.8B; basic EPS: KRW 322.
Gross margin: 42.6% (KRW 16.6B gross profit on KRW 38.9B revenue).
Cash and cash equivalents at period end: KRW 20.9B; total assets: KRW 147.7B.
Dividend per share maintained at KRW 480 for recent years.
Outlook and guidance
Market demand for reliability testing and analysis is expected to grow, driven by AI, 5G, automotive, aerospace, and defense sectors.
Plans to maintain stable dividends and enhance shareholder value through continued investment in R&D and equipment.
Latest events from Quality Reliability Technology
- 2024 H1 revenue reached ₩29.5B with ₩1.4B net income, led by reliability testing services.405100
Q2 2024 - 2024 revenue up 23% and operating income up 534%, driven by advanced semiconductor testing.405100
Q4 2024 - FY2025 revenue rose 5.5% to KRW 68.9B, driven by advanced semiconductor reliability demand.405100
Q4 2025 - 2024 Q3 revenue fell, but operating profit rose on cost controls; R&D and market expansion continue.405100
Q3 2024 - Q1 2026 revenue up 32.7% and net income up 779.7% year-over-year, driven by reliability testing demand.405100
Q1 2026 - 2025 Q3 revenue and profit declined, but R&D investment and equity remain strong.405100
Q3 2025 - Q1 2025 revenue and net income grew on robust semiconductor reliability testing demand.405100
Q1 2025 - H1 2025 revenue reached KRW 32.75B with 17.3% of sales invested in R&D.405100
Q2 2025